Solid Biosciences' shares have taken a hit after early results from a study of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD) fell short.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.